Home
HelpTest Code FMNPP Motor Neuropathy Panel
Specimen Required
Collection Container/Tube: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 4 mL Serum
Collection Instructions:
1. As soon as possible or within 2 hours of specimen collection, centrifuge and aliquot 4 mL serum into a plastic vial.
2. Send refrigerate.
Secondary ID
75811Method Name
Semi-Quantitative Enzyme-Linked Immunosorbent Assay; Quantitative Immunoturbidimetry; Quantitative Capillary Electrophoresis; Qualitative Immunofixation Electrophoresis; Colorimetric Assay
Reporting Name
Motor Neuropathy PanelSpecimen Type
Serum SSTSpecimen Minimum Volume
Serum: 2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum SST | Refrigerated (preferred) | 7 days |
| Frozen | 30 days |
Reject Due To
| Hemolysis | Reject |
| Lipemia | Reject |
| Gross icterus | Reject |
| Contaminated specimens | Reject |
| Heat-inactivated specimens | Reject |
Reference Values
Myelin Associated Glycoprotein (MAG) Antibody, IgM:
0-999 TU
TU=Titer Units
Sulfate-3-Glucuronyl Paragloboside (SGPG) Antibody, IgM:
0.00-0.99 IV
Asialo-GM1 Antibodies, IgG/IgM: 0-50 IV
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GM1 Antibodies, IgG/IgM: 0-50 IV
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GD1a Antibodies, IgG/IgM: 0-50 IV
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GD1b Antibodies, IgG/IgM: 0-50 IV
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GQ1b Antibodies, IgG/IgM: 0-50 IV
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
Immunoglobulin G:
0-2 years: 242-1108 mg/dL
3-4 years: 485-1160 mg/dL
5-9 years: 514-1672 mg/dL
10-14 years: 581-1652 mg/dL
15-18 years: 479-1433 mg/dL
≥19 years: 768-1632 mg/dL
Immunoglobulin A:
0-2 years: 2-126 mg/dL
3-4 years: 14-212 mg/dL
5-9 years: 52-226 mg/dL
10-14 years: 42-345 mg/dL
15-18 years: 60-349 mg/dL
≥19 years: 68-408 mg/dL
Immunoglobulin M:
0-2 years: 21-215 mg/dL
3-4 years: 26-155 mg/dL
5-9 years: 26-188 mg/dL
10-14 years: 47-252 mg/dL
15-18 years: 26-232 mg/dL
> or 19 years: 35-263 mg/dL
Total Protein, Serum:
Refer to report. Reference intervals may vary based on instrumentation.
Albumin:
3.75-5.01 g/dL
Alpha 1 Globulin:
0.19-0.46 g/dL
Alpha 2 Globulin:
0.48-1.05 g/dL
Beta Globulin:
0.48-1.10 g/dL
Gamma:
0.62-1.51 g/dL
Monoclonal Protein:
≤0.00 g/dL
Day(s) Performed
Monday through Sunday
Report Available
3 to 12 daysPerforming Laboratory
ARUP LaboratoriesTest Classification
This test was developed, and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.CPT Code Information
82784 x 3
83516 x 7
84155
84165
86334
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| FMNPP | Motor Neuropathy Panel | Not Provided |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| Z4539 | MAG Antibody, IgM | 17314-6 |
| Z4540 | SGPG Antibody, IgM | 31666-1 |
| Z4541 | Asialo-GM1 Antibodies, IgG-IgM | 44737-5 |
| Z4542 | GM1 Antibodies, IgG-IgM | 63244-8 |
| Z4543 | GD1a Antibodies, IgG-IgM | 48656-3 |
| Z4544 | GD1b Antibodies, IgG-IgM | 26870-6 |
| Z4545 | GQ1b Antibodies, IgG-IgM | 31674-5 |
| Z4546 | Immunoglobulin G | 2465-3 |
| Z4547 | Immunoglobulin A | 2458-8 |
| Z4548 | Immunoglobulin M | 2472-9 |
| Z4549 | Total Protein, Serum | 2885-2 |
| Z4550 | Albumin | 1751-7 |
| Z4551 | Alpha 1 Globulin | 2865-4 |
| Z4552 | Alpha 2 Globulin | 2868-8 |
| Z4553 | Beta Globulin | 2871-2 |
| Z4554 | Gamma | 2874-6 |
| Z6250 | Monoclonal Protein | Not Provided |
| Z4555 | Immunofixation | 25700-6 |
| Z4556 | SPEP-IFE Interpretation | 49275-1 |
| Z4557 | EER Motor Neuropathy Panel | 11526-1 |
Clinical Information
Refer to https://ltd.aruplab.com/
Interpretation
Myelin Associated Glycoprotein Antibody, IgM:
An elevated IgM antibody concentration greater than 999 titer units (TU) against myelin-associated glycoprotein (MAG) suggests active demyelination in peripheral neuropathy. A normal concentration (less than 999 TU) generally rules out an anti-MAG antibody-associated peripheral neuropathy.
Sulfate-3-Glucuronyl Paragloboside Antibody, IgM:
The majority of sulfate-3-glucuronyl paragloboside (SGPG) IgM-positive sera will show reactivity against MAG. Patients who are SGPG IgM positive and MAG IgM negative may have multi-focal motor neuropathy with conduction block.
Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies, IgG/IgM:
Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1), and the neutral glycolipid, asialo GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80 percent of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.